IGC Pharma annual net debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Net Debt Growth & History (IGC)
IGC Pharma's net debt was −$755,000 for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | −$755,000 | — | — |
| 2025 · Mar 31 | 2025-03-31 | −$165,000 | $685,000 | — |
| 2024 | 2024-03-31 | −$850,000 | $1.9M | — |
| 2023 | 2023-03-31 | −$2.7M | $7.1M | — |
| 2022 | 2022-03-31 | −$9.8M | $3.6M | — |
| 2021 | 2021-03-31 | −$13.5M | −$6.8M | — |
| 2020 | 2020-03-31 | −$6.6M | $18.9M | — |
| 2019 | 2019-03-31 | −$25.6M | −$23.9M | — |
| 2018 | 2018-03-31 | −$1.7M | −$1.6M | — |
| 2017 | 2017-03-31 | −$85,920 | $575,544 | — |
| 2016 | 2016-03-31 | −$661,464 | −$1.4M | — |
| 2015 | 2015-03-31 | $779,768 | $1.8M | — |
| 2014 | 2014-03-31 | −$1.0M | $37,856 | — |
| 2013 | 2013-03-31 | −$1.1M | −$501,473 | — |
| 2012 | 2012-03-31 | −$562,948 | $118,993 | — |
| 2011 | 2011-03-31 | −$681,941 | — | — |
IGC Pharma quarterly net debt
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | −$331,000 | −$82,000 | — |
| Q1 2026 · Mar 31 | 2026-03-31 | −$198,000 | −$33,000 | — |
| Q4 2025 · Dec 31 | 2025-12-31 | −$755,000 | −$558,000 | — |
| Q2 2026 · Sep 30 | 2025-09-30 | −$955,000 | $284,000 | — |
| Q1 2026 · Jun 30 | 2025-06-30 | −$249,000 | $1.2M | — |
| Q4 2025 · Mar 31 | 2025-03-31 | −$165,000 | $685,000 | — |
| Q3 2025 | 2024-12-31 | −$197,000 | $801,000 | — |
| Q2 2025 | 2024-09-30 | −$1.2M | $1.4M | — |
| Q1 2025 | 2024-06-30 | −$1.5M | −$211,000 | — |
| Q4 2024 | 2024-03-31 | −$850,000 | $1.9M | — |
| Q3 2024 | 2023-12-31 | −$998,000 | $3.4M | — |
| Q2 2024 | 2023-09-30 | −$2.6M | $3.5M | — |
| Q1 2024 | 2023-06-30 | −$1.3M | $6.2M | — |
| Q4 2023 | 2023-03-31 | −$2.7M | $7.1M | — |
| Q3 2023 | 2022-12-31 | −$4.4M | $6.9M | — |
| Q2 2023 | 2022-09-30 | −$6.1M | $7.7M | — |
| Q1 2023 | 2022-06-30 | −$7.5M | $5.1M | — |
| Q4 2022 | 2022-03-31 | −$9.8M | $3.6M | — |
| Q3 2022 | 2021-12-31 | −$11.3M | −$11.4M | — |
| Q2 2022 | 2021-09-30 | −$13.7M | −$13.7M | — |
| Q1 2022 | 2021-06-30 | −$12.6M | −$11.1M | — |
| Q4 2021 | 2021-03-31 | −$13.5M | −$6.8M | — |
| Q3 2021 | 2020-12-31 | $128,000 | $10.2M | — |
| Q2 2021 | 2020-09-30 | −$35,000 | $14.0M | — |
| Q1 2021 | 2020-06-30 | −$1.5M | $15.0M | — |
| Q4 2020 | 2020-03-31 | −$6.6M | $18.9M | — |
| Q3 2020 | 2019-12-31 | −$10.1M | $17.0M | — |
| Q2 2020 | 2019-09-30 | −$14.0M | −$7.6M | — |
| Q1 2020 | 2019-06-30 | −$16.5M | −$15.5M | — |
| Q4 2019 | 2019-03-31 | −$25.6M | −$23.9M | — |
| Q3 2019 | 2018-12-31 | −$27.0M | −$25.3M | — |
| Q2 2019 | 2018-09-30 | −$6.4M | −$6.2M | — |
| Q1 2019 | 2018-06-30 | −$1.0M | −$851,381 | — |
| Q4 2018 | 2018-03-31 | −$1.7M | −$1.6M | — |
| Q3 2018 | 2017-12-31 | −$1.7M | −$1.4M | — |
| Q2 2018 | 2017-09-30 | −$246,206 | $39,326 | — |
| Q1 2018 | 2017-06-30 | −$169,619 | $547,067 | — |
| Q4 2017 | 2017-03-31 | −$85,920 | $575,544 | — |
| Q3 2017 | 2016-12-31 | −$298,055 | −$876,623 | — |
| Q2 2017 | 2016-09-30 | −$285,532 | −$453,168 | — |
| Q1 2017 | 2016-06-30 | −$716,686 | −$1.6M | — |
| Q4 2016 | 2016-03-31 | −$661,464 | −$1.4M | — |
| Q3 2016 | 2015-12-31 | $578,568 | $1.4M | — |
| Q2 2016 | 2015-09-30 | $167,636 | $1.2M | — |
| Q1 2016 | 2015-06-30 | $926,417 | $3.5M | — |
| Q4 2015 | 2015-03-31 | $779,768 | $1.8M | — |
| Q3 2015 | 2014-12-31 | −$789,073 | −$348,447 | — |
| Q2 2015 | 2014-09-30 | −$994,630 | −$267,862 | — |
| Q1 2015 | 2014-06-30 | −$2.6M | −$1.9M | — |
| Q4 2014 | 2014-03-31 | −$1.0M | $37,856 | — |
| Q3 2014 | 2013-12-31 | −$440,626 | $1.7M | — |
| Q2 2014 | 2013-09-30 | −$726,768 | −$292,771 | — |
| Q1 2014 | 2013-06-30 | −$651,465 | −$132,789 | — |
| Q4 2013 | 2013-03-31 | −$1.1M | −$501,473 | — |
| Q3 2013 | 2012-12-31 | −$2.1M | $1.6M | — |
| Q2 2013 | 2012-09-30 | −$433,997 | −$485,636 | — |
| Q1 2013 | 2012-06-30 | −$518,676 | −$241,557 | — |
| Q4 2012 | 2012-03-31 | −$562,948 | $118,993 | — |
| Q3 2012 | 2011-12-31 | −$3.7M | — | — |
| Q2 2012 | 2011-09-30 | $51,639 | — | — |
| Q1 2012 | 2011-06-30 | −$277,119 | — | — |
| Q4 2011 | 2011-03-31 | −$681,941 | — | — |
IGC Pharma net debt trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's net debt decreased from −$681,941 to −$755,000, a change of −$73,059. The latest reported quarter, Q2 2026 · Jun 30, shows −$331,000.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗